IMPORTANT ADVANCES IN ONCOLOGY 1987 NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IMPORTANT ADVANCES IN ONCOLOGY 1987

Import Adv Oncol; 1-322 1987. Unique Identifier : AIDSLINE ICDB/88640256
Anonymous; No affiliation given

Abstract: Important Advances in Oncology 1987 is the third in a series of annual volumes, each of which contains the most significant changes in oncologic research and practice that have taken place during the preceding year. For this volume, basic research has been selected that describes studies related to immunoglobulin and T-cell receptor genes as they reveal the clonality, lineage, and translocations of lymphoid neoplasms; pleiotropic drug resistance; monoclonal antibodies in the management of epithelial ovarian carcinoma; papilloma viruses; peptide growth factors; and proto-oncogene expression and the development of tumor markers. A review of work on tumor necrosis factor is included because of the substantial recent interest and activity in studying this substance despite the early stage in its clinical development. The clinical progress section contains discussions of nuclear magnetic resonance imaging; induction chemotherapy as initial treatment for advanced head and neck cancer; etiology of colorectal cancer; high-dose chemotherapy with bone marrow support for solid tumors; brachytherapy; PDQ--an innovation in dissemination of cancer information; nonoperative therapy of biliary obstruction; and progress in the development of antiviral therapy for human T cell lymphotropic virus-III-associated diseases.
Keywords: Animal Human Neoplasms/GENETICS/*THERAPY Oncogenes Research MONOGRAPH

KWDanimalhumanneoplasms/genetics/KWDtherapyoncogenesresearchmonograph
880330
M8830437

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .